{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:27:45Z","timestamp":1786739265257,"version":"build-2736575974"},"reference-count":78,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:p>Cystic fibrosis (CF) is a life-threatening genetic disorder caused by mutations in the CFTR gene. This leads to a defective protein that impairs chloride transport, resulting in thick mucus buildup and chronic inflammation in the airways. The review discusses current and future therapeutic approaches for CFTR dysfunction and airway dysbiosis in the era of personalized medicine. Personalized medicine has revolutionized CF treatment with the advent of CFTR modulator therapies that target specific genetic mutations. These therapies have significantly improved patient outcomes, slowing disease progression, and enhancing quality of life. It also highlights the growing recognition of the airway microbiome\u2019s role in CF pathogenesis and discusses strategies to modulate the microbiome to further improve patient outcomes. This review discusses various therapeutic approaches for cystic fibrosis (CFTR) mutations, including adenovirus gene treatments, nonviral vectors, CRISPR\/cas9 methods, RNA replacement, antisense-oligonucleotide-mediated DNA-based therapies, and cell-based therapies. It also introduces airway dysbiosis with CF and how microbes influence the lungs. The review highlights the importance of understanding the cellular and molecular causes of CF and the development of personalized medicine to improve quality of life and health outcomes.<\/jats:p>","DOI":"10.4103\/jfmpc.jfmpc_1085_23","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T06:02:07Z","timestamp":1718344927000},"page":"2200-2208","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Current and future therapeutic approaches of CFTR and airway dysbiosis in an era of personalized medicine"],"prefix":"10.4103","volume":"13","author":[{"given":"Kirti","family":"Upadhyay","sequence":"first","affiliation":[{"name":"Cytogenetics Lab, Centre for Advance Research, King George\u2019s Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitu","family":"Nigam","sequence":"additional","affiliation":[{"name":"Cytogenetics Lab, Centre for Advance Research, King George\u2019s Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surbhi","family":"Gupta","sequence":"additional","affiliation":[{"name":"Cytogenetics Lab, Centre for Advance Research, King George\u2019s Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surya Kant","family":"Tripathi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, King George\u2019s Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Microbiology, King George\u2019s Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin","family":"Puri","sequence":"additional","affiliation":[{"name":"King George\u2019s Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,6,14]]},"reference":[{"key":"R1-20260204","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1186\/s12967-021-03099-4","article-title":"Gene therapy for cystic fibrosis: new tools for precision medicine","volume":"19","author":"Lee","year":"2021","journal-title":"J Transl Med"},{"key":"R2-20260204","doi-asserted-by":"crossref","first-page":"15010","DOI":"10.1038\/nrdp.2015.10","article-title":"Cystic fibrosis","volume":"1","author":"Ratjen","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"R3-20260204","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1126\/science.2570460","article-title":"Identification of the cystic fibrosis gene: Genetic analysis","volume":"245","author":"Kerem","year":"1989","journal-title":"Science"},{"key":"R4-20260204","first-page":"228","article-title":"Mapping of DNA markers linked to the cystic fibrosis locus on the longarm of chromosome 7","volume":"40","author":"Zengerling","year":"1987","journal-title":"Am J Hum Genet"},{"key":"R5-20260204","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet"},{"key":"R6-20260204","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1189\/jlb.71.1.54","article-title":"Expression and functional characterization of CFTR inmast cells","volume":"71","author":"Kulka","year":"2002","journal-title":"J Leukoc Biol"},{"key":"R7-20260204","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1369\/jhc.2009.953455","article-title":"Expression and distribution of cystic fibrosis transmembrane conductance regulator in neurons of the human brain","volume":"57","author":"Guo","year":"2009","journal-title":"J Histochem Cytochem"},{"key":"R8-20260204","doi-asserted-by":"crossref","first-page":"30926","DOI":"10.1038\/srep30926","article-title":"Expression of cystic fibrosis transmembrane conductance regulator in ganglia of human gastrointestinal tract","volume":"6","author":"Xue","year":"2016","journal-title":"Sci Rep"},{"key":"R10-20260204","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1091\/mbc.e14-04-0935","article-title":"From CFTR biology toward combinatorial pharmacotherapy: Expanded classification of cystic fibrosis mutations","volume":"27","author":"Veit","year":"2016","journal-title":"Mol Bio Cell"},{"key":"R11-20260204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/09687688.2013.868055","article-title":"Functional architecture of the CFTR chloride channel","volume":"31","author":"Linsdell","year":"2014","journal-title":"Mol Membr Biol"},{"key":"R12-20260204","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.biocel.2014.01.024","article-title":"On the structural organization of the intracellular domains of CFTR","volume":"52","author":"Moran","year":"2014","journal-title":"Int J Biochem Cell Biol"},{"key":"R13-20260204","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3390\/pharmaceutics15010162","article-title":"Current and future therapeutic approaches of exocrine pancreatic insufficiency in children with cystic fibrosis in the era of personalized medicine","volume":"15","author":"Ritivoiu","year":"2023","journal-title":"Pharmaceutics"},{"key":"R14-20260204","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fphar.2019.00121","article-title":"Emerging therapeutic approaches for cystic fibrosis. From gene editing to personalized medicine","volume":"10","author":"Pranke","year":"2019","journal-title":"Front Pharmacol"},{"key":"R15-20260204","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jconrel.2018.07.001","article-title":"PEGylated enhanced cell penetrating peptide nanoparticles for lunggene therapy","volume":"285","author":"Osman","year":"2018","journal-title":"J Control Release"},{"key":"R16-20260204","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1089\/hum.2020.169","article-title":"Novel lung tropic Adeno-associated virus capsids for therapeutic gene delivery","volume":"31","author":"Carneiro","year":"2020","journal-title":"Hum Gene Ther Sep"},{"key":"R17-20260204","doi-asserted-by":"crossref","first-page":"1015926","DOI":"10.3389\/fphar.2022.1015926","article-title":"Gene therapy for cystic fibrosis: Challenges and prospects","volume":"13","author":"Sui","year":"2022","journal-title":"Front Pharmacol"},{"key":"R18-20260204","doi-asserted-by":"crossref","first-page":"9023","DOI":"10.1128\/JVI.05154-11","article-title":"Enhanced sialic acid-dependent endocytosis explains the increased efficiency of infection of airway epithelia by a novel adeno-associated virus","volume":"85","author":"Dickey","year":"2011","journal-title":"J Virol Sep"},{"key":"R19-20260204","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/thoraxjnl-2016-208406","article-title":"Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis","volume":"72","author":"Alton","year":"2017","journal-title":"Thorax"},{"key":"R20-20260204","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/gt.2017.78","article-title":"Novel GP64 envelope variants for improved delivery to human airway epithelial cells","volume":"24","author":"Sinn","year":"2017","journal-title":"Gene Ther Oct"},{"key":"R24-20260204","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13578-021-00662-w","article-title":"Potential of helper-dependent Adenoviral vectors in CRISPR-cas9-mediated lung gene therapy","volume":"11","author":"Bandara","year":"2021","journal-title":"Cell Biosci"},{"key":"R25-20260204","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jconrel.2015.12.012","article-title":"Non-viral gene therapy: Gains and challenges of non-invasive administration methods","volume":"240","author":"Foldvari","year":"2016","journal-title":"J. Controll Release"},{"key":"R26-20260204","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.coph.2017.10.006","article-title":"Genetic therapies for cystic fibrosis lungdisease","volume":"34","author":"Hart","year":"2017","journal-title":"Curr Opin Pharmacol"},{"key":"R27-20260204","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S2213-2600(15)00245-3","article-title":"Repeated nebulisation of non-viral CFTR genetherapy in patients with cystic fibrosis: A randomised, double-blind, placebo controlled, phase 2b trial","volume":"3","author":"Alton","year":"2015","journal-title":"Lancet Respir Med"},{"key":"R28-20260204","doi-asserted-by":"crossref","first-page":"BSR20160618","DOI":"10.1042\/BSR20160618","article-title":"Enhancement of lung gene delivery after aerosol: A new strategy using non-viral complexes with antibacterial properties","volume":"37","author":"Mottais","year":"2017","journal-title":"Biosci Rep"},{"key":"R29-20260204","doi-asserted-by":"crossref","first-page":"8720","DOI":"10.1073\/pnas.1502281112","article-title":"2015. Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy","volume":"112","author":"Mastorakos","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"R30-20260204","doi-asserted-by":"crossref","first-page":"978","DOI":"10.4187\/respcare.05624","article-title":"Inhaled drug therapy 2016: The year in review","volume":"62","author":"Dhand","year":"2015","journal-title":"Respir Care"},{"key":"R31-20260204","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.1232033","article-title":"RNA-guided human genome engineering via Cas9","volume":"339","author":"Mali","year":"2013","journal-title":"Science"},{"key":"R32-20260204","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nature16526","article-title":"High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects","volume":"529","author":"Kleinstiver","year":"2016","journal-title":"Nature"},{"key":"R33-20260204","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.tcb.2015.07.009","article-title":"Repair pathway choices and consequences at the double-strand break","volume":"26","author":"Ceccaldi","year":"2016","journal-title":"Trends Cell Biol"},{"key":"R34-20260204","doi-asserted-by":"crossref","first-page":"W175","DOI":"10.1093\/nar\/gkz405","article-title":"The gene sculpt suite: A set of tools for genome editing","volume":"47","author":"Mann","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"R35-20260204","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A*T to G*C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"R36-20260204","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"R37-20260204","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"R38-20260204","doi-asserted-by":"crossref","first-page":"e202000940","DOI":"10.26508\/lsa.202000940","article-title":"Evaluating CRISPR-based prime editing for cancer modeling and CFTR repair in organoids","volume":"4","author":"Geurts","year":"2021","journal-title":"Life Sci Alliance"},{"key":"R40-20260204","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat Rev Drug Discov Oct"},{"key":"R41-20260204","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1165\/rcmb.2005-0456OC","article-title":"Antiinflammatory activity of inhaled IL-4 receptor- ?antisense oligonucleotide in mice","volume":"36","author":"Karras","year":"2007","journal-title":"Am J Respir Cell Mol Biol"},{"key":"R42-20260204","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1016\/j.ymthe.2017.11.002","article-title":"Oligonucleotide therapies for the lung: Ready to return to the clinic?","volume":"25","author":"Kumar","year":"2017","journal-title":"Mol Ther"},{"key":"R43-20260204","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jcf.2017.05.003","article-title":"Inhaled ENaC antisense oligonucleotide ameliorates cystic fibrosis-like lung disease in mice","volume":"16","author":"Crosby","year":"2017","journal-title":"J Cyst Fibros Nov"},{"key":"R44-20260204","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/j.jcf.2019.12.012","article-title":"New approaches to genetic therapies for cystic fibrosis","volume":"19","author":"Boyd","year":"2020","journal-title":"J Cyst Fibros"},{"key":"R45-20260204","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3390\/genes9110538","article-title":"Cystic fibrosis gene therapy: Looking back, looking forward","volume":"9","author":"Cooney","year":"2018","journal-title":"Genes"},{"key":"R46-20260204","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1089\/hum.2020.166","article-title":"New directions in pulmonary gene therapy","volume":"31","author":"Vu","year":"2020","journal-title":"Hum Gene Ther"},{"key":"R47-20260204","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.gendis.2018.11.005","article-title":"Delivering on the promise of gene editing for cystic fibrosis","volume":"6","author":"Hodges","year":"2019","journal-title":"Genes Dis"},{"key":"R48-20260204","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.stem.2013.11.002","article-title":"Functional repair of CFTR by CRISPR\/Cas9 in intestinal stem cell organoids of cystic fibrosis patients","volume":"13","author":"Schwank","year":"2013","journal-title":"Cell Stem Cell"},{"key":"R49-20260204","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.omtm.2020.06.022","article-title":"Ready for repair?Gene editing enters the clinic for the treatment of human disease","volume":"18","author":"Ernst","year":"2020","journal-title":"Mol Methods Clin Dev"},{"key":"R50-20260204","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.stem.2020.09.017","article-title":"Derivation of airway basal stem cells from human pluripotent stem cells","volume":"28","author":"Hawkins","year":"2021","journal-title":"Cell Stem Cell"},{"key":"R51-20260204","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.stemcr.2015.02.005","volume":"4","year":"2015","journal-title":"Stem Cell Rep"},{"key":"R52-20260204","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41586-018-0393-7","article-title":"A revised airway epithelial hierarchy includes CFTR-expressing ionocytes","volume":"560","author":"Montoro","year":"2018","journal-title":"Nature"},{"key":"R53-20260204","doi-asserted-by":"crossref","first-page":"639475","DOI":"10.3389\/fphar.2021.639475","article-title":"Treatment of cystic fibrosis: From gene- to cell-based therapies","volume":"12","author":"Allan","year":"2021","journal-title":"Front Pharmacol"},{"key":"R54-20260204","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fphar.2019.00074","article-title":"Challenges facing airway epithelial cell-based therapy for cystic fibrosis","volume":"10","author":"Berical","year":"2019","journal-title":"Front Pharmacol"},{"key":"R55-20260204","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.jcf.2020.12.022","article-title":"Relationship between airway dysbiosis, inflammation and lung function in adults with cystic fibrosis","volume":"20","author":"Frey","year":"2021","journal-title":"J Cyst Fibros"},{"key":"R56-20260204","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1146\/annurev-physiol-021115-105238","article-title":"The microbiome and the respiratory tract","volume":"78","author":"Dickson","year":"2016","journal-title":"Annu Rev Physiol"},{"key":"R57-20260204","doi-asserted-by":"crossref","first-page":"eaav3488","DOI":"10.1126\/scitranslmed.aav3488","article-title":"Mucus accumulation in the lungs precedes structural changes and infection in children with cystic fibrosis","volume":"11","author":"Esther","year":"2019","journal-title":"Sci Transl Med"},{"key":"R58-20260204","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.chom.2017.10.001","article-title":"Three-dimensional microbiome and metabolome cartography of a diseased human lung","volume":"22","author":"Garg","year":"2017","journal-title":"Cell Host Microbe"},{"key":"R59-20260204","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nri3769","article-title":"Host\u2013microorganism interactions in lung diseases","volume":"14","author":"Marsland","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"R60-20260204","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S2213-2600(16)30081-9","article-title":"The nasal microbiota in infants with cystic fibrosis in the first year of life: a prospective cohort study","volume":"4","author":"Mika","year":"2016","journal-title":"Lancet Respir Med"},{"key":"R61-20260204","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1093\/jac\/dkr318","article-title":"Bacteriophages as vehicles of the resistome in cystic fibrosis","volume":"66","author":"Rolain","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"R62-20260204","doi-asserted-by":"crossref","first-page":"e36313","DOI":"10.1371\/journal.pone.0036313","article-title":"The airway microbiota in cystic fibrosis: A complex fungal and bacterial community\u2014Implications for therapeutic management","volume":"7","author":"Delhaes","year":"2012","journal-title":"PLoS One"},{"key":"R63-20260204","doi-asserted-by":"crossref","first-page":"e0116029","DOI":"10.1371\/journal.pone.0116029","article-title":"Comparison of microbiomes from di_erent niches of upper and lower airways in children and adolescents with cystic fibrosis","volume":"10","author":"Boutin","year":"2015","journal-title":"PLoS One"},{"key":"R64-20260204","doi-asserted-by":"crossref","first-page":"1602235","DOI":"10.1183\/13993003.02235-2016","article-title":"Concordance between upper and lower airway microbiota in infants with cystic fibrosis","volume":"49","author":"Prevaes","year":"2017","journal-title":"Eur Respir J"},{"key":"R65-20260204","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1186\/s40064-015-1207-0","article-title":"Insights into the respiratory tract microbiota of patients with cystic fibrosis during early Pseudomonas aeruginosa colonization","volume":"4","author":"Keravec","year":"2015","journal-title":"Springer Plus"},{"key":"R66-20260204","doi-asserted-by":"crossref","first-page":"e000374","DOI":"10.1136\/bmjresp-2018-000374","article-title":"Porphyromonas, a potential predictive biomarker of pseudomonas aeruginosa pulmonary infection in cystic fibrosis","volume":"6","author":"Keravec","year":"2019","journal-title":"BMJ Open Resp Res"},{"key":"R67-20260204","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41564-018-0292-6","article-title":"Prediction of the intestinal resistome by a three-dimensional structure-basedmethod","volume":"4","author":"Rupp\u00e9","year":"2019","journal-title":"Nat Microbiol"},{"key":"R68-20260204","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3390\/medicina54050072","article-title":"Lower airway virology in health and disease\u2014From invaders to symbionts","volume":"54","author":"Jankauskait\u0117","year":"2018","journal-title":"Medicina"},{"key":"R69-20260204","doi-asserted-by":"crossref","first-page":"e00824","DOI":"10.1128\/mBio.00824-17","article-title":"First insights into the diverse human archaeome: Specific detection of archaea in the gastrointestinal tract, lung, and nose and on skin","volume":"8","author":"Koskinen","year":"2017","journal-title":"mBio"},{"key":"R70-20260204","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ccm.2022.06.005","article-title":"Novel Applications of Biomarkers and Personalized Medicine in Cystic Fibrosis","volume":"43","author":"Guimbellot","year":"2022","journal-title":"Clin Chest Med"},{"key":"R71-20260204","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1002\/ppul.23505","article-title":"Therapeutic challenges posed by critical drug-drug interactions in cystic fibrosis","volume":"51","author":"Jordan","year":"2016","journal-title":"Pediatr Pulmonol"},{"key":"R72-20260204","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"R73-20260204","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"R74-20260204","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacftor\/ivacaftor in people with cystic fibrosis","volume":"205","author":"Nichols","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"R75-20260204","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"R76-20260204","doi-asserted-by":"crossref","first-page":"e122695","DOI":"10.1172\/jci.insight.122695","article-title":"Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTR","volume":"3","author":"Donaldson","year":"2018","journal-title":"JCI Insight"},{"key":"R77-20260204","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa043891","article-title":"Mucus clearance and lung function in cystic fibrosis with hypertonic saline","volume":"354","author":"Donaldson","year":"2006","journal-title":"N Engl J Med"},{"key":"R78-20260204","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/cid\/ciu944","article-title":"Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor","volume":"60","author":"Heltshe","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R79-20260204","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1164\/rccm.201906-1206OC","article-title":"Pulmonary outcomes associated with long-term azithromycin therapy in cystic fibrosis","volume":"201","author":"Nichols","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"R80-20260204","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1164\/rccm.201802-0215OC","article-title":"Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE Randomized Trial","volume":"198","author":"Mayer-Hamblett","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"R81-20260204","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jama.2010.563","article-title":"Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: A randomized controlled trial","volume":"303","author":"Saiman","year":"2010","journal-title":"JAMA"},{"key":"R82-20260204","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jcf.2019.03.009","article-title":"An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB)","volume":"18","author":"Rosenfeld","year":"2019","journal-title":"J Cyst Fibros"},{"key":"R83-20260204","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-2600(18)30202-9","article-title":"Ivacaftor treatment of cystic fibrosis in children aged 12 to<24 months and with a CFTR gating mutation (ARRIVAL): A phase 3 single-arm study","volume":"6","author":"Rosenfeld","year":"2018","journal-title":"Lancet Respir Med"}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_1085_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:27:23Z","timestamp":1786735643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_1085_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":78,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_1085_23","relation":{},"ISSN":["2249-4863","2278-7135"],"issn-type":[{"value":"2249-4863","type":"print"},{"value":"2278-7135","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"2023-07-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}